Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous EBV-specific T cells
- Development stage
- Unknown
- Lead developer
- Australasian Leukaemia & Lymphoma Group
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous EBV-specific T cells is an investigational adoptive cell therapy being developed for the treatment of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL). The therapy involves harvesting a patient's own T lymphocytes, which are then expanded and selected ex vivo for their ability to recognize and target EBV-encoded antigens. These specialized T cells are reinfused into the patient to eliminate EBV-infected malignant B cells. In clinical investigation by the Australasian Leukaemia and Lymphoma Group (ALLG), this therapy is used as part of a sequential multimodality regimen following induction with tislelizumab, rituximab, and chemoimmunotherapy.
- Other names
- autologous Epstein-Barr virus-specific T cellsEBV-CTLsautologous EBV-CTLsEBV-specific T lymphocytes
02
Targets
pMHC (Peptide-MHC complex family)BARF1 (Epstein-Barr virus BARF1 protein)pMHC-I (Peptide–MHC class I complex)Epstein-Barr virus latent membrane protein 1 peptide-human leukocyte antigen complex
Beyond the preview
Go deeper on autologous EBV-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous EBV-specific T cells.